Complete Exhibition Package including travel/cargo options.
All Services connected to your stand - Security, Electricity, Cleaning, Exhibitor Badges...
All Networking Functions - Power Breakfast/Lunch, Happy Hours, Advanced Appointments
Seminar Room & Exhibitors' Lounge
Online Service Manual, where you have full control
Personalised Visitor Promotion - we do basic Research, Issue Invitations on your behalf, escorted VIP Tours
Visitor Pre-Registration with online and print Show Previews with direct link to exhibitors
High gloss & comprehensive Show Directory - distributed free of charge
Exhibitor Briefings: via Email alerts & SE-Asian Market Orientation by Frost & Sullivan, Tour of a major hospital
The KLCC - the best venue in Asia.
Prefix:     
Name:     
Title:     
Organisation:     
Street:     
City:     
Zip Code:     
E-mail:     
 
The Malaysian Pharma Market continues to demonstrate robust growth rates of between 8-12% pa. This is much higher than its immediate neighbours.

Malaysia is the 6th largest importer of pharmaceuticals in the region.

Imports make up over 65% of the total market.

Market value of around USD1.50bn

Prescription drugs account for around 75%

AFTA (Asean Free Trade Area and FTAs with key markets are also make it easier for foreign manufacturers to enter these lucrative markets.

Government’s commitment to the development of a local pharmaceutical R&D base will attract foreign investment.

Malaysian firms lack sufficient capacity to expand overseas, and will instead continue to focus on the local, mainly generic market.

There are around 300 registered pharmaceutical companies in Malaysia, of which 100 are local. The top 40 pharmaceutical companies hold some 30% of the market. The Malaysian pharmaceutical industry is expanding at an average of 10% annually. Multinational corporations (MNCs) control about 70% of the pharmaceutical market, which includes over-the-counter (OTC) drugs.

Opportunities generated by the Malaysian government's objectives to increase the sector in order to become the leading regional provider of products and services within life sciences.

The Life Sciences Industry in Malaysia

In general the Malaysian life sciences industry enjoy attention by the government. Not only because sub sectors such as pharmaceuticals and medical technology are significant contributors to the national economy, but also because the government prioritises business activities that are characterised by high technology and by being knowledge based.

The Malaysian pharmaceutical industry is expanding at a high rate and it is expected that it in 2005 will amount to US$539.47 million compared to US$315.79 million in 2000.

With the admission of Malaysia as a member of the Pharmaceutical Inspection Convention and Pharmaceutical Inspection Cooperation/Scheme (PIC/S) in January 2002, the country's exports of pharmaceutical products received a boost, especially among the member countries, which include the EU, Australia and Canada.

The principal regulatory authority on the production, import and sale of pharmaceuticals (including traditional medicines) in Malaysia is theDrug Control Authority (DCA) of the Ministry of Health.As at 31st. December, 2004, a total of 205 pharmaceutical companies with Good Manufacturing Practices certification have registered with the DCA

Of these, a total of 74 companies are involved in the production of modern medicines comprising mainly analgesics, antacids, anti - hypertensives, diuretics, antibiotics and anti-histamines in the form of tablets, capsules, drops, powders, creams, ointments, injectibles, syrups, ophthalmic and nasal preparations. The remaining 131 companies are local traditional and herbal medicinemanufacturers.

Malaysia's Intellectual Propertylaws conform to international standards and provide adequate protection to both local and foreign investors.

Currently, the manufacture of pharmaceuticals and related products (which include pharmaceutical goods, clinical diagnostic reagents, gelatine or gelatine products, intravenous, dialysis or irrigating solutions, vaccines, medicaments) are eligible for normal Pioneer Status or Investments Tax Allowance incentives.

The development, testing and production of pharmaceuticals promoted under biotechnology is eligible for High Technology Pioneer Status or Investments Tax Allowance incentives.

Copyrights © 2008 by ABC Exhibitions. All rights reserved.
You are visitor no.
13591
since July 1st 2008